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Summary
Epilepsy is one of the most serious neurological conditions and
has an impact not only on the affected individual but also on
the family and, indirectly, on the community. A global approach
to the individual must take into account cognitive problems,
psychiatric comorbidities and all psychosocial complications
that often accompany epilepsy. We discuss psychosocial issues
in epilepsy with special focus on the relationship between
stigma and psychiatric comorbidities. Social barriers to optimal
care and health outcomes for people with epilepsy result in
huge disparities, and the public health system needs to invest
in awareness programmes to increase public knowledge and
reduce stigma in order to minimise such disparities.
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Epilepsy is among the most common serious neurological con‐
ditions with incidence rates, in high-income countries, ranging
between 40 and 70 per 100 000 persons per year and generally
higher in young children and in the elderly.1–3 In resource-poor
countries, the incidence is usually much higher, often above
120/100 000/year, and in high-income countries, poor people also
seem to have a higher incidence.4,5 Poor sanitation, inadequate
health delivery systems and higher risk of brain infections and
infestations may contribute to this.1,6 Prevalence studies have
reported lifetime rates between 4 and 10/1000 in developed
countries,2,7 but data from resource-poor countries clearly suggest
higher lifetime prevalence rates in the region of 23.2–32.1/10008 up
to 57/1000 in some selected cases in rural areas.9
Many people with epilepsy live a normal life, but there is no
doubt that the long-term prognosis of epilepsy is poor in many
cases owing to increased morbidity and mortality.10 This can be
because of physical causes (e.g. fractures, scalding, bruising) as
well as comorbidity with other systemic diseases11 and increased
psychosocial problems.12 People with epilepsy, particularly if
chronic, have an increased risk of premature death.6,13,14 Sudden
unexpected death, trauma, suicide, pneumonia and status epilep-
ticus have been identified as being more common in people with
epilepsy.14,15 Symptomatic epilepsy may reduce life expectancy by
up to 18 years.11 Little is known about mortality in resource-poor
countries as only a few adequate studies have been carried out to
address this issue. Circumstantial evidence, however, suggests that
the mortality rate is higher, helping to explain the discrepancy
between the higher incidence and relatively low prevalence of
active epilepsy in these countries.1
In May 2015, the World Health Assembly approved the WHO
Resolution on the Global Burden of Epilepsy which provides a
powerful tool to engage national governments into implementing
effective actions to improve medical and social services for people
with epilepsy, promote public awareness about epilepsy and
allocate resources to epilepsy research.16 The resolution calls on
the WHO Secretariat to continue to lead and coordinate support
to member states in addressing the global burden of epilepsy so
that people with epilepsy can receive timely treatment and can
benefit from educational and occupational opportunities, free
from stigma and discrimination.
The global perspective
Apart from good seizure control, numerous factors are involved
in quality of life (QoL) of people with epilepsy. It is now well
recognised that other factors, such as comorbid depression and
adverse effects of medications, are far stronger predictors.17 Even
in those in whom remission is achievable, if this is at the expense
of unacceptable side-effects, adherence and QoL remain poor.
Successful integration of people with epilepsy into society is
another important goal in epilepsy care. Educational level, intellec-
tual ability, psychological stability, family and social support, the
ability to overcome stigma, transportation and mobility issues, and
employment opportunities are important determinants of success-
ful integration.18 The combination of these factors influences the
life of people with epilepsy and what they consider meaningful.19
For this reason, sport and leisure is becoming a new topic in
epilepsy care and the International League against Epilepsy has a
specific task force dedicated to Epilepsy and Sport and a report is
now available.20
The QoL of people with epilepsy also appears to be related to
the level of social support they receive through the various societal
structures, including emotional support, informational support,
instrumental support, appraisal, social companionship and affec-
tionate support.21 Social support mechanisms help people to over‐
come many of the difficulties they encounter. Individuals with good
social support usually have an increased sense of control over their
lives, enabling them to have better coping mechanisms for handling
adversities.21 It is now clear that people with the highest level of
social support have significantly lower reported stigma scores.22
Epilepsy is a condition still highly stigmatised, and stigma
greatly affects the QoL of people with epilepsy, leading to increased
anxiety and depression and poor adherence with medication.23
Unfortunately, even today, stigma is present in both high-income
and resource-poor countries.1 Stigma is not only responsible for
poor QoL but also seems to play a role in mood and anxiety pro‐
blems in both people with epilepsy and their caregivers. Perceived
stigma is also responsible for increased rates of aggressive behaviour
associated with depression and anxiety.24 In low- and middle-
income countries, 20% of mothers of children with epilepsy feel
stigmatised because of their child’s neurological condition,25 and
the caregiver’s perception of burden, together with the level
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of family function, are indirectly correlated with depressive
symptoms in people with epilepsy via the mediating effect of
caregiver depression.26 This is also present in high-income coun-
tries where social aspects of stigma are an important determinant of
anxiety and depression.27
The US Centers for Disease Control and Prevention, Epilepsy
Program, pointed out that one in five of those with epilepsy lives
alone and less than one in four live in households with two adults
and children.28 Adults with epilepsy living alone may be at in‐
creased risk of injury associated with uncontrolled seizures, mental
distress associated with social isolation, lower QoL and early
mortality. Stigma affects attitude towards epilepsy and the more
intimate life domains such as cohabitation and marriage. A number
of studies have shown that people with epilepsy are less likely to
be married and people suffering from the enacted stigma are
significantly more likely to get divorced in comparison with
others.29–31
In resource-poor countries, stigma directly affects access to
healthcare32,33 and probably contributes to the discrepancy
between the incidence and prevalence of epilepsy in lower-income
regions of the world because diagnoses and clinical information are
sometimes unreliable.34 As already stated, perceived stigma is a
problem even in high-income countries and is probably a major
determinant of poor adherence with medications.23 The informa-
tion–motivation–behavioural skills model is a useful framework
for understanding the pathways linking perceived stigma and
adherence in the population with epilepsy.35 Living in a European
country with better health system performance and higher health
expenditure per capita does not necessarily lead to a reduction in
perceived discrimination, unless the public health system invests in
awareness programmes to increase public knowledge and reduce
stigma.36 Low socio-economic status alone does not account for
felt stigma, but depressive symptoms and poor social supports
have the greatest impact on reported felt stigma in people with
epilepsy.37 Social barriers to optimal care and health outcomes for
people with epilepsy result in huge disparities.38 Disparities are
a complex phenomenon that requires research and action. A sys‐
tematic review has identified five domains of potential disparities
in epilepsy care: access to medical and surgical treatment, out-
comes following medical/surgical treatment, attitudes/knowledge
about epilepsy, epidemiology and disability.39 Data on these do‐
mains were, however, limited. For example, a US national study
has shown that White people and those privately insured were
found to be more likely to have surgery compared with their
respective minority and publicly insured counterparts.40 Further-
more, robust data collection and surveillance to identify points of
intervention are urgently needed.
Cognitive problems
About 40% of people with epilepsy aged between 4 and 15 years
have one or more additional neurological problems, the most
common being intellectual disabilities, speech and language diffi-
culties or other specific cognitive disabilities.1 In addition, intellec-
tually disabled individuals are at an increased risk of behavioural
problems.41 Those severely affected have higher healthcare needs
than others because of the concomitant presence of other neurolo-
gical disabilities (i.e. feeding and swallowing difficulties, inability
to walk).42
Epilepsy can have an impact on cognition in several ways. A
degree of impairment in cognitive functions is frequently reported by
people with epilepsy, ranging between 44% for difficulties in learning
and psychomotor retardation to 59% for sleepiness or tiredness.43,44
In clinical practice, the majority of cognitive problems have multi-
factorial origins with many different variables often interlinked.44
Cognitive dysfunction in epilepsy is generally regarded as either trait
dependent or state dependent.45 Trait-dependent dysfunction is a
stable condition owing to the underlying brain disorder, while state-
dependent dysfunction is a potentially reversible condition owing
to modifiable factors such as anti-epileptic drugs (AEDs), seizure
frequency and pattern, and psychiatric comorbidities.
Whether poorly controlled epilepsy is associated with progres-
sive cognitive deterioration is still controversial, and this has been
demonstrated only for some specific syndromes: mesial temporal
lobe epilepsy and epileptic encephalopathies.46 Different epileptic
encephalopathies seem to have specific patterns of cognitive deficits
such as short-term visuospatial memory problems, executive
dysfunction and frontal lobe dysfunction in Unverricht–Lundborg
syndrome,47,48 language dysfunction in Landau–Kleffner syn-
drome49 and poor language acquisition and visuospatial defects in
Dravet50 and Rett syndrome.51 Finally, epileptic encephalopathies
associated with frequent and uncontrolled seizures during sleep
are characterised by memory and language problems.52
Cognitive problems are important in the long-term manage-
ment of people with epilepsy, having an impact on QoL and every‐
day functioning.53,54 A US study showed that a self-management
intervention targeting cognitive dysfunction can significantly im‐
prove not only cognitive performance but also QoL.55 Access to
investigations, appropriate testing and review are important parts
of the management.
Epilepsy has also a clear impact on relatives and carers of
people with epilepsy, especially when seizures start during child-
hood. A Swedish study showed that mothers and fathers of
children with drug-resistant epilepsy have poorer QoL compared
with population norms, and symptoms of anxiety seem to be
common especially among mothers.56
Psychiatric problems
Psychiatric disorders are relatively frequent comorbidities in
epilepsy, with a lifetime history identified in one in three people
with epilepsy.57 Mood and anxiety disorders are the most frequently
reported58 for both biological and psychosocial reasons. The burden
of stigma, social limitations and discrimination in epilepsy lead to
demoralisation and poor self-esteem, but the pathophysiology of
epilepsy per se is interlinked with mood problems as demonstrated
by neuroanatomical and neurochemical principles. The involve-
ment of the temporal lobes59 and the psychotropic effects of AEDs60
seem to be relevant contributors to the increased rates of psychiatric
problems in epilepsy but much remains unknown regarding the
role of shared versus syndrome-specific variables and the role of
cortico-subcortical networks. In addition, a number of epidemiolo-
gical studies have suggested that the relationship between epilepsy
and psychiatric problems is not necessarily unilateral but rather
bidirectional and some people may present with a psychiatric
disorder before the emergence of seizures.61–63
Depression is an important predictor of poor QoL,64 seizure
severity,65 drug-resistance66 and a poor outcome after epilepsy
surgery.67 Nonetheless, mood disorders are still under-recognised,
under-treated and sometimes fully ignored, unless they are severe
enough to reach medical attention. A number of reasons can
explain the diagnostic delay and inaccuracy, including individuals’
reluctance spontaneously to volunteer information about existing
psychiatric problems, a paucity (or total lack) of training for
the treating neurologist to recognise psychiatric symptoms and a
lack of time in very busy clinics to screen for them. The result is
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that epilepsy is often complicated and burdened by psychiatric
disturbances or behavioural problems that are not adequately
addressed or managed.
Suicide is a severe complication of untreated and undiagnosed
depression. In the context of epilepsy, suicide is gaining increasing
attention, and it has been recently reinvigorated by the Food and
Drug Administration alert on a supposedly increased risk of suicidal
ideation and behaviour in people taking AEDs.68 In the general
population, suicide is the 11th cause of death and the second in
the age group between 25 and 34 years.69 It is now evident that
the overall risk of death by suicide is about three times higher in
people with epilepsy than in the general population.70–72 Several
studies have attempted to identify reasons for this increased risk. In
the general population, about 90% of people who die by suicide have
at least one psychiatric disorder at the time.73 Epilepsy is burdened
by psychiatric comorbidities, but it is unlikely that such a problem
is the only responsible element. A Danish study reported that the
rate ratio of suicide in people with epilepsy is still doubled even after
excluding people with psychiatric comorbidity and adjusting for
various factors.72 Some have suggested a link with temporal lobe
epilepsy,70 but a recent study, using retrospective and prospective
methods, found no epilepsy-related factors.74 The issue of epilepsy
and suicide is still far from being elucidated, but it is likely to be
multifactorial with biological, constitutional and psychosocial
variables being implicated. It seems evident that suicide prevention
is another relevant issue in epilepsy care deserving further clinical
attention.
People with epilepsy historically have been considered to have
an increased risk of developing psychotic disorders. Epidemiologi-
cal evidence suggests that the incidence of non-organic, non-
affective psychoses, including schizophrenia and schizophrenia
spectrum disorders, is generally over-represented among people
with epilepsy compared with the general population or other
chronic medical conditions.75 A family history of psychoses and a
family history of epilepsy were significant risk factors for psychosis
suggesting strong neurobiological underpinnings.76 In general
terms, psychoses represent a rare but serious complication of
epilepsy. Close attention to the relationship between psychotic
symptoms and seizure pattern is crucial to identify seizure-based
phenomena such as postictal psychoses or the forced normalisation
phenomenon.77 Chronic interictal schizophrenia-like psychoses
can be occasionally seen and deserve careful consideration.
The increasing attention to the psychiatric comorbidities of
epilepsy brings to light the issue of double stigma. No studies
investigated the relative contribution of the two conditions, epilepsy
and mental health issues, but the problem of double stigma is well-
known in other medical conditions such as obesity and mental
health78 or the comorbidity between HIV and tuberculosis79 in low-
income countries. Double stigma means double challenge and for
this reason it becomes even more important to invest energies and
resources.
Epilepsy is one of the most common neurological conditions,
and it has an impact not only on the individual with epilepsy but
also on the family and, indirectly, on the community. A global
approach to the individual must take into account the cognitive
problems and psychiatric comorbidities that often accompany
epilepsy. The burden of epilepsy concerns not only the physical
hazards of epilepsy but also the psychosocial consequences
involved, such as the negative attitudes of people towards the
patients, manifested as social stigma, social isolation and lack of
support. Social barriers to optimal care and health outcomes for
people with epilepsy result in huge disparities, and the public health
system should invest in awareness programmes to increase public
knowledge and reduce stigma in order to minimise such disparities.
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